TS
STOK icon

Thomas Steyer’s Stoke Therapeutics STOK Stock Holding History

Thomas Steyer’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9,000
Closed -$293K – 174
2026
Q1 		$293K Hold
9,000
– – ﹤0.01% 121
2025
Q4 		$286K Buy
+9,000
New +$271K ﹤0.01% 115

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Thomas Steyer's STOK Position: Q2 2026 in Review

Thomas Steyer sold out of Stoke Therapeutics (STOK) in Q2 2026, closing a stake of 9,000 shares — an estimated $293K sold.

Thomas Steyer first reported a position in STOK in Q4 2025 and held it in 2 quarters. The position peaked at $293K in Q1 2026. 196 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Thomas Steyer reported no remaining Stoke Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Thomas Steyer sold 9,000 Stoke Therapeutics shares in Q2 2026, an estimated $293K.
  • Thomas Steyer first reported a position in Stoke Therapeutics in Q4 2025 and held it in 2 quarters.
  • Thomas Steyer's Stoke Therapeutics position peaked at $293K in Q1 2026.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.